Immunocore strengthens IP position in the field of TCR-based therapeutics
September 05, 2018 07:00 ET
|
Immunocore Limited
Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and...
Immunocore strengthens IP position in the field of TCR-based therapeutics
September 05, 2018 02:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and...
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
August 20, 2018 07:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK...
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
August 20, 2018 02:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK...